Eight Recent Deals Tapping AI/ML For R&D

As the improvements made possible with artificial intelligence and machine learning for biopharmaceutical research and development become clear, deal making in the space has skyrocketed. S&P Global projects that business development around AI/ML will total $22bn by 2027. But the group also warns that big pharma is making the lion’s share of these investments, and could be building significant competitive advantages. These recent deals highlight the range of deal activity going on in the AI/ML field.

On 26 September, the US Health and Human Services Administration unveiled the Transforming Antibiotic R&D with Generative AI to stop Emerging Threats (TARGET) project. To be led by HHS’s Advanced...